147 related articles for article (PubMed ID: 27747761)
1. Current Practice Patterns and Educational Needs of Rheumatologists Who Manage Patients with Rheumatoid Arthritis.
Glauser TA; Ruderman EM; Kummerle D; Kelly S
Rheumatol Ther; 2014 Dec; 1(1):31-44. PubMed ID: 27747761
[TBL] [Abstract][Full Text] [Related]
2. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey.
Maetzel A; Bombardier C; Strand V; Tugwell P; Wells G
J Rheumatol; 1998 Dec; 25(12):2331-8. PubMed ID: 9858426
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis.
Huang Y; Chatterjee S; Agarwal SK; Chen H; Johnson ML; Aparasu RR
Explor Res Clin Soc Pharm; 2023 Sep; 11():100296. PubMed ID: 37521021
[TBL] [Abstract][Full Text] [Related]
4. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
5. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
6. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
7. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
[TBL] [Abstract][Full Text] [Related]
8. Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.
Nash P; Nicholls D
Int J Rheum Dis; 2013 Dec; 16(6):652-61. PubMed ID: 24382276
[TBL] [Abstract][Full Text] [Related]
9. Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey.
Saraux A; Devauchelle-Pensec V; Engerran L; Flipo RM
J Rheumatol; 2006 Jul; 33(7):1258-65. PubMed ID: 16783865
[TBL] [Abstract][Full Text] [Related]
10. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists.
Kamal KM; Madhavan SS; Hornsby JA; Miller LA; Kavookjian J; Scott V
Joint Bone Spine; 2006 Dec; 73(6):718-24. PubMed ID: 16997599
[TBL] [Abstract][Full Text] [Related]
11. Individual variations in treatment decisions by Swedish rheumatologists regarding biological drugs for rheumatoid arthritis.
Kalkan A; Hallert E; Carlsson P; Roback K; Sjöwall C
Scand J Rheumatol; 2015; 44(4):265-70. PubMed ID: 26202443
[TBL] [Abstract][Full Text] [Related]
12. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
[TBL] [Abstract][Full Text] [Related]
13. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
[TBL] [Abstract][Full Text] [Related]
14. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
15. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
Pope JE; Hong P; Koehler BE
J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
[TBL] [Abstract][Full Text] [Related]
16. Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent.
Senbel E; Durand F; Roux B; Badaoui FZ; Fautrel B
Rheumatol Ther; 2021 Jun; 8(2):921-935. PubMed ID: 33939171
[TBL] [Abstract][Full Text] [Related]
17. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
[TBL] [Abstract][Full Text] [Related]
18. Treatment Response to Tumor Necrosis Factor Inhibitors and Methotrexate Monotherapy in Adults With Juvenile Idiopathic Arthritis: Data From NOR-DMARD.
Bardan I; Fagerli KM; Sexton J; Kvien TK; Bakland G; Mielnik P; Hu Y; Lien G; Flatø B; Molberg Ø; Kristianslund EK; Aga AB
J Rheumatol; 2023 Apr; 50(4):538-547. PubMed ID: 36379571
[TBL] [Abstract][Full Text] [Related]
19. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
20. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events.
Yazici Y; Erkan D; Paget SA
Arthritis Rheum; 2003 Oct; 48(10):2769-72. PubMed ID: 14558081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
